

Diffuse Large B-Cell Lymphoma (DLBCL) Lymphoma

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04660799 YO42207

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter China-only study to investigate the PK, efficacy and safety of SC rituximab versus IV rituximab, both in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated participants with CD20 positive DLBCL. Participants will be randomized to receive eight cycles of rituximab SC or rituximab IV combined with six or eight cycles of standard CHOP chemotherapy. After the end of study treatment, participants will be followed-up every 3 months for 6 months.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04660799 YO42207
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 80 Years

Healthy Volunteers
No